Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Firms / ABV, LLC

ABV, LLC

Institutional venture firmNew York, NYabvlp.comSEC venture capital fund adviser

venture manager, reported GAV $116M across 7 vehicles

Importance
23
moderate
Active deployment
0
low
Emerging
0
low
Completeness
56
elevated
Freshness
97
high
Research priority
5
low
Identity and regulatory footprint
Headquarters
New York, NYadviserinfo.sec.gov
Office address
1 ROCKEFELLERPLAZA, SUITE 1040, New York, NY, 10020adviserinfo.sec.gov
Business phone
212-688-8897adviserinfo.sec.gov
Website
HTTP://WWW.ABVLP.COM
SEC adviser type
exempt reporting adviseradviserinfo.sec.gov
SEC exemption claimed
venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
Latest Form ADV
Mar 30, 2022
Private funds reported
7 (6 venture capital funds)adviserinfo.sec.gov
Private fund gross assets
$116Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
Owners on Schedule A
Digitalis, LLC (Manager), C; High Mountain, LLC (Manager), C
business phone
212-688-8897adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
no observed deals yet
Stated (the firm’s website)
Sectors
not stated or not yet read
Stages
not stated or not yet read
Geography
not stated
Check size
not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors: no observed deals yet
lead rate n/afollow-on rate n/anew logos, 12 months 0
Funds and vehicles
7 reported, 1 no longer reported
VehicleTypeVintageLifecycleReported GAVOwnersForm D soldLatest Form D
Ascent Biomedical Ventures I Annex, L.P.Continuation vehicle2014 adv first reportedHarvest$17.4M
Mar 30, 2022
31unknownunknown
Ascent Biomedical Ventures II, L.P.FundunknownUnknown$36.7M
Mar 30, 2022
53unknownunknown
Ascent Biomedical Ventures I, L.P.FundunknownUnknown$25.3M
Mar 30, 2022
84unknownunknown
Ascent Biomedical Ventures II NY, L.P.FundunknownUnknown$17.4M
Mar 30, 2022
2unknownunknown
Ascent Biomedical Ventures Synecor, L.P.FundunknownUnknown$7.5M
Mar 30, 2022
36unknownunknown
Ascent Biomedical Holdings, L.P.SPV or co-invest vehicle · ADV: Other Private FundunknownUnknown$7.0M
Mar 30, 2022
6unknownunknown
Ascent Biomedical Ventures I NY, L.P.FundunknownUnknown$4.8M
Mar 30, 2022
2unknownunknown
Abvs Fund (cayman), Ltd.Feeder or parallelunknownWound down$0
Mar 31, 2021
5unknownunknown
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
3 current, 1 departed
Geoffrey Smith
Manager · since Oct 1, 2004
Partner
FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Steven Hochberg
Manager · since Oct 1, 2004
Partner
FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Jeffrey Sauerhoff
Chief Financial Officer · since Oct 1, 2004
Platform and operations
FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
1 departed (kept with end dates)
Investments on record
0 edges, 0 companies, 0 partner-attributed
No investment on record yet. Edges arrive from the firm’s portfolio page, financing announcements, and Form D board seats.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
1 disclosed
Timeline
11 dated events
  1. Mar 30, 2022
    Abvs Fund (cayman), Ltd. no longer reported on Form ADV by ABV, LLC
    Fund no longer reportedFundsInferenceAbvs Fund (cayman), Ltd.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  2. May 27, 2020
    Lawrence Steven Atinsky (Chief Legal Officer) no longer on Schedule A of ABV, LLC
    Person leftPeopleInferenceLawrence Steven AtinskySEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  3. Mar 31, 2014
    Ascent Biomedical Ventures I Annex, L.P. first reported on Form ADV by ABV, LLC (Venture Capital Fund), GAV $12,388,054
    Fund first reported on Form ADVFundsFactAscent Biomedical Ventures I Annex, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  4. Mar 30, 2012
    Ascent Biomedical Ventures II NY, L.P. first reported on Form ADV by ABV, LLC (Venture Capital Fund), GAV $3,846,966
    Fund first reported on Form ADVFundsFactAscent Biomedical Ventures II NY, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  5. Mar 30, 2012
    Abvs Fund (cayman), Ltd. first reported on Form ADV by ABV, LLC (Venture Capital Fund), GAV $1,459,144
    Fund first reported on Form ADVFundsFactAbvs Fund (cayman), Ltd.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  6. Mar 30, 2012
    ABV, LLC first filed Form ADV (ERA, venture capital fund adviser exemption)
    First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  7. Mar 30, 2012
    Ascent Biomedical Ventures Synecor, L.P. first reported on Form ADV by ABV, LLC (Venture Capital Fund), GAV $3,694,037
    Fund first reported on Form ADVFundsFactAscent Biomedical Ventures Synecor, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  8. Mar 30, 2012
    Ascent Biomedical Ventures I, L.P. first reported on Form ADV by ABV, LLC (Venture Capital Fund), GAV $56,049,145
    Fund first reported on Form ADVFundsFactAscent Biomedical Ventures I, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  9. Mar 30, 2012
    Ascent Biomedical Ventures II, L.P. first reported on Form ADV by ABV, LLC (Venture Capital Fund), GAV $21,595,288
    Fund first reported on Form ADVFundsFactAscent Biomedical Ventures II, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  10. Mar 30, 2012
    Ascent Biomedical Holdings, L.P. first reported on Form ADV by ABV, LLC (Other Private Fund), GAV $5,934,258
    Fund first reported on Form ADVFundsFactAscent Biomedical Holdings, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  11. Mar 30, 2012
    Ascent Biomedical Ventures I NY, L.P. first reported on Form ADV by ABV, LLC (Venture Capital Fund), GAV $12,745,860
    Fund first reported on Form ADVFundsFactAscent Biomedical Ventures I NY, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
  1. Sep 12, 2026
    Institutional venture firm (confirmed, 95%, cls-1)
    venture manager, reported GAV $116M across 7 vehicles
Evidence
25 observations from 1 source
Every observation behind this profile, with its source, date and class
FactValueEffectiveClassSource
SEC exemption claimedventure_capital_fund_adviserMar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
SEC adviser typeexempt_reporting_adviserMar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
First Form ADV filing2012-03-30Mar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Adv history loadedadv-hist-1Sep 12, 2026FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Latest Form ADV filing2022-03-30Mar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Venture share of reported funds1Mar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Business phone212-688-8897Mar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
HeadquartersNew York, NYMar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Office address1 ROCKEFELLERPLAZA, SUITE 1040, New York, NY, 10020Mar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Legal formLimited Liability CompanyMar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private funds reported7Mar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private fund gross assets (reported)$116MMar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Venture funds reported6Mar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
WebsiteHTTP://WWW.ABVLP.COMMar 30, 2022FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)